10,928 reports of this reaction
7.0% of all DALFAMPRIDINE reports
#1 most reported adverse reaction
GAIT DISTURBANCE is the #1 most commonly reported adverse reaction for DALFAMPRIDINE, manufactured by Merz Pharmaceuticals, LLC. There are 10,928 FDA adverse event reports linking DALFAMPRIDINE to GAIT DISTURBANCE. This represents approximately 7.0% of all 157,067 adverse event reports for this drug.
Patients taking DALFAMPRIDINE who experience gait disturbance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GAIT DISTURBANCE is moderately reported among DALFAMPRIDINE users, representing a notable but not dominant share of adverse events.
In addition to gait disturbance, the following adverse reactions have been reported for DALFAMPRIDINE:
The following drugs have also been linked to gait disturbance in FDA adverse event reports:
GAIT DISTURBANCE has been reported as an adverse event in 10,928 FDA reports for DALFAMPRIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GAIT DISTURBANCE accounts for approximately 7.0% of all adverse event reports for DALFAMPRIDINE, making it one of the most commonly reported side effect.
If you experience gait disturbance while taking DALFAMPRIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.